Lobbying Information
Subject Matters
- Aboriginal Affairs
- Agriculture
- Arts and Culture
- Broadcasting
- Constitutional Issues
- Consumer Issues
- Defence
- Education
- Employment and Training
- Energy
- Environment
- Financial Institutions
- Fisheries
- Forestry
- Government Procurement
- Health
- Immigration
- Industry
- Infrastructure
- Intellectual Property
- Internal Trade
- International Relations
- International Trade
- Justice and Law Enforcement
- Labour
- Mining
- Regional Development
- Science and Technology
- Small Business
- Sports
- Taxation and Finance
- Telecommunications
- Tourism
- Transportation
Subject Matter Details
Legislative Proposal, Bill or Resolution
- Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry
- Canada's Food and Consumer Safety Action Plan as it relates to the regulation and protection of biopharmaceutical products
- Income Tax Act as it relates to biopharmaceutical products
- Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
Legislative Proposal, Bill or Resolution, Regulation
- Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies
- Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals
Policies or Program
- Anti-Counterfeit Trade Agreement (ACTA) as it concerns counterfeit drugs
- Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease
- Canada-United States Regulatory Cooperation Council (RCC) initiatives related to the regulation of biopharmaceutical products
- Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships
- Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework
- Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH)
- Free trade treaty agreement as they relate to the North American Free Trade Agreement (NAFTA) and free trade negotiations as it relates to India, the European Union, Japan, MERCOSUR and the Trans-Pacific Partnership
- Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB)
- Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits
- Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations
- The government's Science and Technology strategy as it relates to the biopharmaceutical industry
- World Health Organization (WHO) issues concerning pharmaceuticals as it relates to Counterfeits, Access to Medicines, and the Intergovernmental Working Group (IGWG)
- World Intellectual Property Organization (WIPO) issues concerning the protection of and access to intellectual property
- World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility"
Regulation
- Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
- Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry
- New Substances Notification Regulations as it relates to the biopharmaceutical industry
- Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
- Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive
- Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products
- Smart Regulations as it relates to the biopharmaceutical industry
Communication Techniques
-
Written communication
-
Oral communication
-
Grass-roots communication
Government Institutions
-
Agriculture and Agri-Food Canada (AAFC)
-
Canada Revenue Agency (CRA)
-
Canadian Institutes of Health Research (CIHR)
-
Canadian International Trade Tribunal (CITT)
-
Competition Tribunal (CT)
-
Employment and Social Development Canada (ESDC)
-
Environment and Climate Change Canada (ECCC)
-
Finance Canada (FIN)
-
Fisheries and Oceans Canada (DFO)
-
Global Affairs Canada (GAC)
-
Health Canada (HC)
-
House of Commons
-
Innovation, Science and Economic Development Canada (ISED)
-
Justice Canada (JC)
-
National Research Council (NRC)
-
Natural Resources Canada (NRCan)
-
Natural Sciences and Engineering Research Council (NSERC)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Public Health Agency of Canada (PHAC)
-
Public Services and Procurement Canada (PSPC)
-
Senate of Canada
-
Statistics Canada (StatCan)
-
Treasury Board Of Canada Secretariat (TBS)
-
Veterans Affairs Canada (VAC)
In-house Organization Details
Description of the organization's activities
Innovative Medicines Canada represents Canada’s innovative pharmaceutical industry. We help our members discover, develop, and deliver innovative medicines and vaccines. Our membership consists of more than 50 companies, from established organizations to fledgling startups, all of whom are revolutionizing healthcare through the discovery and development of new medicines and vaccines. Guided by a strict Code of Ethical Practices, we work with governments, insurance companies, healthcare professionals and stakeholders to advance the field and enhance the wellbeing of Canadians. We are committed to being valued partners in Canada’s healthcare system. We aim to achieve these goals by forming effective alliances and supporting policies, improving Canada’s regulatory environment, widen access to innovative medicines and protect intellectual property.
Responsible officer name and position during the period of this registration
RUSSELL WILLIAMS,
PRESIDENT
Organization's membership or classes of membership
(a) Full Membership: Full membership is open to innovative pharmaceutical Persons which research, develop, manufacture and/or distribute pharmaceutical prescription preparations under their own labels in Canada. (b) Biopharmaceutical Membership: Biopharmaceutical membership is open to Persons who are engaged, in research and development of pharmaceutical products and/or biopharmaceutical health care products with the aim of producing, manufacturing or distributing the same under its own label. (c) Medical Research Affiliate Membership: Medical research affiliate membership is open to non-profit organizations engaged in research which have a relationship or are connected with hospitals, universities, research institutes, recognized health/disease organizations, or divisions or units thereof, whose membership, in the determination of the Board, would be consistent with the objects of the Association and would enhance the ability of the Association to attain such objects, and who are engaged in health research. (d) Associate Membership: Associate membership is open to Persons who do not qualify under any of the foregoing membership categories and whose membership, in the determination of the Board, would be consistent with the objects of the Association and would enhance the ability of the Association to attain such objects. Without limiting the generality of the foregoing, Associate Members may include contract research organizations, contract manufacturing organizations and clinical research organizations who supply goods and/or services to Full Members or Biopharmaceutical Members and other stakeholder groups which are appropriate in the determination of the Board.
Government funding
No government funding was received during the last completed financial year.
In-house Organization Contact Information
Address:
55 Metcalfe St.
Suite 1220
Ottawa, ON K1P 6L5
Canada
Telephone number:
613-236-0455
Ext.
425
Fax number:
613-236-6756
Lobbyists Details
Employees who lobby for the organization
- Frédéric Alberro,
Director, Québec, Government Affairs |
No public offices held
- Sarah E Douglas,
Manager of Media Relations |
Public offices held
- Joe Farago,
Executive Director, Healthcare Innovation |
No public offices held
- Declan Hamill,
Chief of Staff and Vice President, Legal Affairs |
Public offices held
- Keith McIntosh,
Executive Director, Scientific & Regulatory Affairs |
No public offices held
- Glenn Monteith,
Vice President, Innovation & Health Sustainability |
No public offices held
- Chrisoula Nikidis,
Executive Director, Ethics & Compliance |
No public offices held
- Isabelle Robillard,
A/Vice President, Public Affairs |
Public offices held
- Alison Sargent,
Executive Director, Engagement |
No public offices held
- Hugh Scott,
Executive Director, Strategic Alliances |
Public offices held
- Brett Skinner,
Executive Director, Health and Economic Policy |
Public offices held
- Kathleen Sullivan,
Executive Director, Innovation and National Policies |
No public offices held
